| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.3M | — | -45.1% |
| R&D Expense | $18.3M | — | -15.6% |
| SG&A Expense | $6.6M | — | -9.1% |
| Operating Income | -$21.6M | — | +5.8% |
| Net Income | -$19.9M | — | -5.5% |
| EPS (Basic) | -$0.29 | — | +3.3% |
| EPS (Diluted) | -$0.29 | — | +3.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $87.7M | +8.4% | +43.6% |
| Current Assets | $188.1M | +15.2% | -16.6% |
| Total Assets | $222.2M | +12.1% | -14.1% |
| Current Liabilities | $64.4M | +7.8% | -9.7% |
| Total Liabilities | $298.6M | -2.6% | -6.8% |
| Stockholders' Equity | -$76.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$25.3M | — | -5.4% |
| Capital Expenditures | $0 | — | -100.0% |
| Investing Cash Flow | -$17.7M | — | -160.3% |
| Financing Cash Flow | $49.8M | — | — |
| Free Cash Flow | -$25.3M | — | -5.3% |
| -23.9% |